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Abstract
Most breast cancer patients in sub-Saharan Africa are diagnosed at advanced stages
after prolonged symptomatic periods. In the multicountry African Breast Cancer-
Disparities in Outcomes cohort, we dissected the diagnostic journey to inform
downstaging interventions. At hospital presentation for breast cancer, women recal-
led their diagnostic journey, including dates of first noticing symptoms and health-
care provider (HCP) visits. Negative binomial regression models were used to identify
correlates of the length of the diagnostic journey. Among 1429 women, the median
(inter-quartile range) length (months) of the diagnostic journey ranged from 11.3
(5.7-21.2) in Ugandan, 8.2 (3.4-16.4) in Zambian, 6.5 (2.4-15.7) in Namibian-black to
5.6 (2.3-13.1) in Nigerian and 2.4 (0.6-5.5) in Namibian-non-black women. Time from
first HCP contact to diagnosis represented, on average, 58% to 79% of the diagnostic
journey in each setting except Nigeria where most women presented directly to the
diagnostic hospital with advanced disease. The median number of HCPs visited was
1 to 4 per woman, but time intervals between visits were long. Women who attrib-
uted their initial symptoms to cancer had a 4.1 months (absolute) reduced diagnostic
journey than those who did not, while less-educated (none/primary) women had a
3.6 months longer journey than more educated women. In most settings the long
journey to breast cancer diagnosis was not primarily due to late first presentation but
to prolonged delays after first presentation to diagnosis. Promotion of breast cancer
awareness and implementation of accelerated referral pathways for women with sus-
picious symptoms are vital to downstaging the disease in the region.
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1 | INTRODUCTION
In high-income countries (HICs), most breast cancer (BC) patients are
diagnosed at an early stage,1 when the disease is potentially curable.2
In contrast, in sub-Saharan Africa (SSA), most BC women are diag-
nosed at advanced stages.3 Delays in seeking care, and in getting a
definitive diagnosis, are the major drivers of advanced stage at diag-
nosis, with studies in HICs having shown that a time interval greater
than 3 months between symptom discovery and diagnosis is associ-
ated with advanced-stage disease and poor outcomes.4 The Breast
Health Global Initiative has emphasized the need for downstaging
interventions which promote early diagnosis and timely access to
appropriate treatment in low- and middle-income countries (LMICs).5
However, to implement those in SSA, it is vital to understand the
array of personal, sociocultural, and economic barriers on a woman's
journey from symptom onset to cancer diagnosis. During this diagnos-
tic period, “delays” may occur either before or after the first contact
with a health-care provider (HCP), hereafter referred to as the pre-
contact and post-contact intervals. Few SSA studies have examined
the diagnostic period, and they involved small numbers of patients, no
standardized collection of data on key events along the diagnostic
journey and limited data on potential correlates.6
The African Breast Cancer-Disparities in Outcomes (ABC-DO)
study is a multicountry prospective cohort of BC patients in SSA,7
which obtained recalled information on the navigational pathway to
BC diagnosis. In a previous ABC-DO analysis, poor BC awareness, low
educational level and unskilled employment were identified as drivers
of late-stage diagnosis with their mediating pathway being mainly
through prolonged time to diagnosis.8,9 The main aims of the present
analysis are to characterize and dissect the navigational path to BC
diagnosis and to identify the main drivers of its length to inform can-
cer control policies in the region.
2 | MATERIALS AND METHODS
2.1 | Study participants and data collection
A detailed protocol of the ABC-DO study has been published.7 Briefly,
women aged ≥18 years with histologically confirmed or suspected BC
were recruited between September 2014 and September 2017,
through hospitals located in five SSA countries: Namibia (Windhoek
Central Hospital, Windhoek), Uganda (Mulago Hospital and the
Uganda Cancer Institute, Kampala), Nigeria (Abia State University
Teaching Hospital and the Maranatha private clinic, Aba, and the Fed-
eral Medical Centre, Owerri), Zambia (Cancer Diseases Hospital and
University Teaching Hospital, Lusaka, and Kabwe General Hospital,
Kabwe) and South Africa (Chris Hani Baragwanath Academic Hospital,
Soweto). The overall response rate was 99%. The present analysis
excludes data from South Africa (as this site used a different baseline
questionnaire) and from Kabwe General Hospital (as recruitment was
not clinic/hospital-based). The study populations will be referred to
hereafter as Nigerian, Ugandan, Zambian, Namibian-black and
Namibian-non-black women.
ABC-DO study implementation, management and data collection
were enabled via a specifically tailored m-health mobile phone applica-
tion. Participants completed a face-to-face baseline interview at, or near,
the time of the first visit to the participating hospital for possible BC
diagnosis. This interview captured information on sociodemographic
variables as well as recalled information on the diagnostic journey (eg,
nature and date of first symptom, dates of all HCP visits) as detailed in
Tables 1 and 2. Information on TNM BC stage at diagnosis was
extracted from clinical records.
TABLE 1 Characteristics of the ABC-DO study participants at the
time of cohort recruitment (not including South Africa)
N = 1429 Percenta
ABC-DO population group
Namibia-black women 371 25.9
Namibia-non-black women 96 6.7
Nigeria 397 27.8
Uganda 400 28.0
Zambia 165 11.6
Sociodemographic
Age at diagnosis: mean (SD) 50.1 (13.9)
Low SEP (vs medium/high)b 810 56.7
Not married (vs married)c 710 49.7
Having any children living at home
(vs none)
1096 76.7
Primary/no education
(vs secondary/higher)
628 44.0
Working in unskilled employment
(vs skilled)
1007 70.5
Health-related
Recent birth (<3 years prior to BC
diagnosis)
176 12.3
Having a personal or family history of
BC (vs no)
174 12.2
Positive HIV status (vs negative) 136 9.5
(Continues)
What's new?
In sub-Saharan Africa, most women with breast cancer are
diagnosed long after symptoms first arise. Here, the authors
studied the diagnostic journey for breast cancer among the
African Breast Cancer-Disparities in Outcome cohort. This is
the largest study to quantify the length of the diagnostic
journey across various settings in sub-Saharan Africa. Time
to final diagnosis decreased substantially when a woman rec-
ognized her symptoms as cancer. Most delays, they found,
were due to extended time between first examination and
final diagnosis. Promotion of breast cancer awareness among
both women and healthcare providers could help reduce
these delays.
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The term “patient delay” is often used in HICs with universal
access to free health care to refer to the time interval from symptom
recognition to presentation to a HCP, as its length is essentially driven
by patient-mediated factors. In contrast, the terms “provider delay,”
“health-system delay” or “diagnostic delay” are often used to refer to
the time interval from presentation to definitive diagnosis, as its
length is driven predominantly by health system-mediated factors.
However, these terms may not properly capture conditions in most
SSA settings—that is, without free access to health care, the length of
each interval is likely to be the result of a complex interplay between
patient and health system drivers. For instance, a woman may delay
presentation not only because of patient-related factors (eg, lack of
BC awareness) but also because of lack of a HCP in her area of resi-
dence. Similarly, a woman who first presents with a suspicious cancer
may delay final diagnosis due to fear of its consequences (eg, mastec-
tomy, death) or desire to try first an informal HCP (eg, traditional
healer). Hence, to avoid any a priori judgement on the reasons underly-
ing the length of these time intervals, the diagnostic journey of a
woman with a suspicious BC was divided into a pre-contact interval
(date of symptom discovery to date of first HCP visit) and a post-
contact interval (date of first HCP visit to date of diagnosis). HCP con-
tacts included those with either the formal or the informal health system
(Table 2). The date of final diagnosis was defined according to the
European Network of Cancer Registries guidelines,10 that is, prioritizing
date of biopsy/cytology or date of hospital admission. If histological
confirmation was not available (12.7% [n = 182]), diagnosis was based
on the clinical history or imaging examinations (eg, mammography).
Women were excluded from this analysis if: their first reported
symptom occurred >5 years (n = 70) previously (likely related to a pre-
vious condition); the date of symptom discovery was missing (n = 6);
or, due to errors, the recorded date of symptom discovery was later
than the date of diagnosis (n = 7). A further 43 women were excluded
from the post-contact interval analyses because the date of diagnosis
preceded the self-reported date of the first HCP visit.
2.2 | Statistical methods
The primary outcomes were the lengths (in months) of the diagnostic
journey, and of its two components: the pre- and post-contact inter-
vals. As the distributions of these lengths were positively skewed,
medians (inter-quartile ranges [IQR]) are reported. The cumulative
probability of obtaining a diagnosis by time since symptom recogni-
tion, and time since first HCP contact, were estimated using Kaplan-
Meier. Negative binomial regression models were fitted to identify
woman-level correlates of interval lengths. These models yielded
incidence rate ratios (IRRs) which can be interpreted as an estimate
of the ratio of interval lengths. Variables within groups of
sociodemographic, health-related, knowledge and belief factors
(Table 1) were highly correlated. Hence, minimally adjusted models,
which adjusted for study population and age, were fitted first to
identify the variable within each group with the strongest associa-
tion with interval lengths. Thereafter, fully adjusted models were
fitted which further controlled for the variables identified by the
minimally adjusted models, that is, educational level, ever-suffering
from a non-human immunodeficiency virus (HIV) comorbidity, and
attributing the initial symptom(s) to cancer. Odds ratio (OR) for the
association between advanced-stage (III/IV) relative to early stage
(I/II) at diagnosis and length of the diagnostic journey were esti-
mated using logistic regression models. Analyses were conducted in
Stata version 14.2.
TABLE 1 (Continued)
N = 1429 Percenta
Having ever had other chronic
comorbidities (vs never)d
740 51.8
Knowledge and beliefs
Heard previously about BC (vs no/don't
know)
1176 82.3
Know someone with BC (vs no/don't
know)
663 46.4
Thinks BC is common (vs no/don't
know)
577 40.3
Thinks BC is curable (vs no/don't know) 754 52.8
Attributed first symptom(s) to cancer
(vs no/don't know))
144 10.1
Belief in traditional medicine/healing
(vs no/don't know)
346 24.2
Belief in spiritual/faith healing
(vs no/don't know)
1010 70.7
Being Muslim (vs no)e 54 13.5
Breast symptom and final diagnosis
Self-recognition of symptoms
(vs screen/CBE detection)f
1399 97.9
First change noticed: breast lump
(vs no)
1230 86.1
Final diagnosis: Benign condition 33 2.3
Final diagnosis: BC 1396 97.7
Presenting with advanced BC stage
(TNM III/IV; vs TNM I/II)g
831 63.2
Abbreviations: BC, breast cancer; CBE, clinical breast examination; HCP,
health-care provider; SEP, socioeconomic position.
aColumn percentages unless stated otherwise.
bCalculated as setting-specific tertiles (low, medium and high) of the distri-
bution of a SEP score (range: 0-9) based on the following self-reported
possessions and facilities: home ownership; indoor water; flush toilet; elec-
tricity; vehicle; refrigerator; landline; gas or electric stove; and a bed.
cMarital status at enrolment defined as married or not married (ie, single,
divorced or widowed).
dHaving ever suffered from one of the following non-HIV chronic condi-
tions: hypertension, heart disease, diabetes, chronic anemia, chronic
obstructive pulmonary disease (COPD, eg, chronic bronchitis, emphy-
sema), asthma, hepatitis B or C, tuberculosis, other chronic infection, other
cancer, other chronic disease.
ePercentage restricted to the Ugandan setting, the only with a sizeable
Muslim population.
fFor 30 women (including 15 Namibian-non-black and 8 Namibian-black
women) the breast abnormality was first detected through mammo-
graphic/ultrasound screening or a routine CBE.
gPercentage out of all women with a final BC diagnosis and with known
stage (n = 1314; information on stage was missing for 81 women: 32 from
Uganda, 23 from Zambia and 26 from Nigeria).
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3 | RESULTS
3.1 | Study participants
In all, 1429 women were included in the analysis (Table 1). Mean
age at diagnosis was 50.1 years, 44% reported low education, 71%
believed in spiritual or faith healing (range: 50% in Uganda to 96%
in Zambia) and 24% believed in traditional medicine (12% in
Namibia to 38% in Uganda). A breast lump was the first symptom
noticed by 86% of the participants. Only 10% attributed their symp-
toms to cancer (3% in Nigeria to 14% in Namibian-black and 33% in
Namibian-non-black women). In all, 98% of BCs were symptomatic
detections.
3.2 | Navigational nodes to BC diagnosis
Most women reported first approaching a close relative/friend before
visiting a HCP. Few women first visited an informal HCP except in
Uganda (14%) (Table 2). Half of the participants reported having expe-
rienced barriers to first visiting a HCP (multiple answers possible); the
most common for Namibian-black and Ugandan women were lack of
F IGURE 1 Left panel: Median (IQR) length (in months) of the diagnostic journey from symptom discovery to diagnosis (breast cancer or
other), and of its pre- and post-contact components, in the ABC-DO study, by population group. Right Panel: Cumulative probabilities of: A, a
definitive diagnosis by time since self-recognition of a suspicious symptom (diagnostic interval); B, a first visit to a HCP by time since discovery of
a suspicious symptom (pre-contact interval); and C, a definitive diagnosis by time since first visit to a HCP (post-contact interval) [Color figure can
be viewed at wileyonlinelibrary.com]
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transport (22% and 12%, respectively) and treatment/transport costs
(18% and 19%, respectively), while in Zambia and Nigeria the most
common were pain and/or fear (18% and 11%, respectively). Of the
1134 participants who had visited other HCPs prior to the study hos-
pital, 40% reported inappropriate outcomes (eg, told not to worry,
wrong diagnosis) of their first visit (range: 57% in Uganda to 17% in
Namibian-non-black women). The median number of HCP visited per
woman ranged from 1 in Nigeria to 4 in Uganda and Namibian-black
women.
3.3 | Length of the diagnostic journey
Lengths of the diagnostic journey (Figure 1, left panel) were shortest
for Namibia-non-blacks (median [months]: 2.4) and longest in Uganda
(11.3). Consequently, the percent of women diagnosed within
3 months of symptom recognition ranged from 59% in Namibia-non-
black women to 11% in Uganda (Figure 1, right panel). The diagnostic
journey was much shorter for women whose breast abnormality was
first detected during a routine hospital visit (screen-detected/CBE,
30 women including 15 Namibian-non-black and 8 Namibian-black)
than for symptomatic women, with medians (IQR) of 1.6 (0.3-5.9) and
7.3 (3.1-16.7) months, respectively.
3.4 | Length of the diagnostic journey and BC
stage at diagnosis
Among women with malignant BC, 65% had advanced disease
(Stages III/IV), with this percent being highest in Nigerian women
(76%) and lowest in Namibian-non-black women (26%). Excluding
screen-detected women, the odds of being diagnosed with Stage
III/IV BC increased with increasing length of the diagnostic journey
(age-population-adjusted OR (95% confidence interval [CI]): 1 (ref-
erence), 1.32 (0.93-1.86), 1.75 (1.25-2.45) and 1.98 (1.45-2.70) for
<3, 3 to <6, 6 to <12 and ≥12 months, respectively; P-for-trend
<.001), with no clear evidence of between-population group
heterogeneity.
F IGURE 2 Median (IQR) time intervals between first visits to consecutive HCP, by total number of HCPs visited, among ABC-DO
symptomatic women. Total number of HCP visited includes the study hospital. Outlier values were excluded and estimates for categories with
<10 women were omitted [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 3 Associations between woman-level factors and length of the diagnostic journey to breast cancer, and its pre-contact and post-
contact intervals, among symptomatic women in the ABC-DO cohort
Variable
Study
population
group
Pre-diagnostic interval Pre-contact interval Post-contact interval
IRR (95% CI)a IRR (95% CI)a IRR (95% CI)a
Overall Group-specific Phet
b Overall Group-specific Overall Group-specific
(n = 1399)c (n = 1399)c (n = 1356)c,d
Sociodemographic
Age (10 years
increase)
1.32 (1.02, 1.69) .148 1.26 (0.89, 1.79) 1.35 (0.94, 1.93)
Low SEP (vs medium/
high)
1.12 (1.00, 1.25) .306 1.10 (0.93, 1.30) 1.22 (1.03, 1.43)
Not married (vs
married)
1.07 (0.96, 1.20) <.001 1.06 (0.91, 1.24) 1.11 (0.95, 1.31)
Namibia-non-
blacks
2.21 (1.23, 4.00) 2.63 (1.22, 5.64) 1.96 (0.85, 4.52)
Namibia-blacks 1.39 (1.10, 1.74) 1.28 (0.90, 1.80) 1.50 (1.10, 2.05)
Nigeria 0.75 (0.60, 0.94) 0.70 (0.54, 0.91) 0.91 (0.60, 1.36)
Uganda 1.04 (0.88, 1.23) 1.15 (0.91, 1.47) 0.96 (0.75, 1.21)
Zambia 1.07 (0.79, 1.44) 1.09 (0.63, 1.87) 1.04 (0.70, 1.54)
Any children living at
home (yes vs no)
0.97 (0.86, 1.10) .86 1.01 (0.85, 1.19) 0.92 (0.77, 1.11)
Primary/no education
(vs secondary/
higher)
1.24 (1.10, 1.40) .037 1.16 (0.98, 1.37) 1.35 (1.13, 1.61)
Namibia-non-
blacks
0.89 (0.40, 1.98) 0.75 (0.27, 2.07) 0.90 (0.31, 2.65)
Namibia-blacks 1.47 (1.16, 1.86) 1.83 (1.30, 2.57) 1.21 (0.86, 1.69)
Nigeria 1.16 (0.89, 1.53) 1.12 (0.81, 1.55) 1.33 (0.80, 2.20)
Uganda 1.20 (1.00, 1.45) 0.91 (0.70, 1.18) 1.45 (1.13, 1.88)
Zambia 1.37 (1.00, 1.87) 1.00 (0.56, 1.80) 1.71 (1.13, 2.57)
Working in unskilled
employment
(yes vs no)
1.10 (0.96, 1.26) .302 1.22 (1.01, 1.47) 1.06 (0.86, 1.29)
Knowledge and beliefs
Ever heard about BC
(yes vs no)
1.05 (0.92, 1.21) .015 0.89 (0.74, 1.08) 1.28 (1.04, 1.57)
Namibia-non-
blacks
— — —
Namibia-blacks 1.06 (0.79, 1.43) 1.01 (0.64, 1.60) 1.20 (0.81, 1.79)
Nigeria 1.08 (0.83, 1.40) 0.93 (0.68, 1.26) 1.30 (0.82, 2.06)
Uganda 1.19 (0.97, 1.46) 0.99 (0.74, 1.33) 1.40 (1.04, 1.89)
Zambia 0.85 (0.54, 1.33) 0.92 (0.40, 2.10) 0.95 (0.51, 1.76)
Know someone with
BC
1.03 (0.92, 1.14) .916 0.93 (0.81, 1.08) 1.12 (0.96, 1.32)
Thinks BC is common 0.98 (0.87, 1.10) <.001 0.78 (0.67, 0.92) 1.14 (0.97, 1.36)
Namibia-non-
blacks
0.31 (0.14, 0.65) 0.35 (0.13, 0.95) 0.19 (0.06, 0.58)
Namibia-blacks 1.10 (0.88, 1.39) 0.91 (0.64, 1.27) 1.32 (0.97, 1.80)
Nigeria 0.88 (0.67, 1.16) 0.89 (0.65, 1.22) 0.75 (0.45, 1.26)
Uganda 1.15 (0.96, 1.37) 0.82 (0.64, 1.05) 1.50 (1.17, 1.93)
Zambia 0.97 (0.71, 1.33) 0.78 (0.44, 1.39) 1.04 (0.70, 1.57)
Thinks BC is curable 0.96 (0.86, 1.08) .174 0.93 (0.80, 1.09) 0.96 (0.81, 1.14)
Attributed symptom(s)
to cancer
0.56 (0.47, 0.67) .115 0.50 (0.39, 0.64) 0.62 (0.47, 0.80)
(Continues)
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TABLE 3 (Continued)
Variable
Study
population
group
Pre-diagnostic interval Pre-contact interval Post-contact interval
IRR (95% CI)a IRR (95% CI)a IRR (95% CI)a
Overall Group-specific Phet
b Overall Group-specific Overall Group-specific
(n = 1399)c (n = 1399)c (n = 1356)c,d
Belief in spiritual
medicine
1.06 (0.94, 1.19) .346 0.97 (0.82, 1.15) 1.11 (0.93, 1.32)
Belief in traditional
medicine
1.10 (0.98, 1.25) .007 1.03 (0.87, 1.22) 1.24 (1.03, 1.48)
Namibia-non-
blacks
0.24 (0.06, 0.91) 0.09 (0.01, 0.75) 0.40 (0.08, 2.12)
Namibia-blacks 0.89 (0.65, 1.20) 1.03 (0.65, 1.64) 0.70 (0.46, 1.07)
Nigeria 1.42 (1.11, 1.81) 1.20 (0.89, 1.62) 1.92 (1.23, 3.00)
Uganda 0.89 (0.65, 1.20) 0.94 (0.74, 1.21) 1.12 (0.88, 1.42)
Zambia 1.08 (0.78, 1.49) 0.95 (0.51, 1.75) 1.21 (0.79, 1.85)
Muslim (vs other
religions)e
0.76 (0.60, 0.97) n.a. 0.94 (0.67, 1.32) 0.69 (0.48, 0.97)
Health related
Recent birth (<3 years) 1.02 (0.85, 1.21) .104 1.08 (0.84, 1.38) 0.95 (0.73, 1.22)
Other chronic
comorbidities (ever
vs never)
0.91 (0.81, 1.02) .297 0.83 (0.71, 0.98) 0.99 (0.84, 1.17)
Personal or known
family history of BC
1.09 (0.92, 1.28) .261 0.88 (0.70, 1.11) 1.33 (1.05, 1.70)
HIV positive 1.04 (0.87, 1.25) .022 1.18 (0.92, 1.51) 0.96 (0.74, 1.25)
Namibia-non-
blacks
— — —
Namibia-blacks 0.93 (0.68, 1.26) 1.11 (0.70, 1.76) 0.77 (0.50, 1.19)
Nigeria 1.14 (0.61, 2.13) 0.64 (0.31, 1.35) 2.16 (0.72, 6.47)
Uganda 0.77 (0.60, 1.00) 0.77 (0.53, 1.13) 0.71 (0.49, 1.03)
Zambia 1.77 (1.17, 2.68) 2.12 (0.97, 4.62) 1.60 (0.93, 2.75)
Symptom related
First symptom
recognized was
breast lump
(yes vs no)f
1.16 (0.99, 1.36) .574 1.42 (1.14, 1.76) 1.04 (0.82, 1.31)
Navigation-related
Urban residence 0.99 (0.88, 1.11) .957 1.09 (0.93, 1.28) 0.95 (0.81, 1.13)
First contact
Primary HCP 1 (ref.) .409 1 (ref.) 1 (ref.)
Secondary HCP 1.04 (0.92, 1.18) 1.29 (1.08, 1.53) 0.87 (0.73, 1.05)
Informal HCP 1.27 (1.00, 1.62) 1.07 (0.77, 1.50) 1.49 (1.05, 2.11)
Abbreviations: BC, breast cancer; HCP, health care provider; n.a., not applicable; ref., reference category; SEP, socioeconomic position; —, estimates based
on <10 women omitted.
aIncidence rate ratios (IRR), with 95% confidence intervals (CI), adjusted for study population group, age (in four categories: 18-39; 40-49; 50-59; 60+),
educational level (primary or none vs secondary or higher), having suffered from a non-HIV chronic comorbidities (ever vs never) and attributing first breast
symptom(s) to cancer (yes vs no).
bP-value for interaction with study population group.
cExcludes 30 women whose symptoms were first discovered by a routine clinical breast examination or through screening mammography/ultrasound (see
Results section).
dExcludes a further 43 women whose date of final diagnosis preceded the self-reported date of their first HCP visit (see Methods section).
eIRR (95% CI) estimates for the Ugandan population group only as this is the only one with a sizeable Muslim population (n = 395 for the pre-diagnostic
and the pre-contact intervals; n = 386 for the post-contact interval).
fExcludes an additional eight women with missing data for this variable.
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3.5 | Partitioning the diagnostic journey into pre-
and post-first HCP contact intervals
The median post-contact interval represented at least 60% of the
diagnostic journey in all settings except Nigeria, where the pre-
contact interval dominated (Table 2). Although the number of HCP
visited was not excessive, the time intervals between visits to consec-
utive HCPs were long (Figure 2). For instance, the median length
(in months) between visits to the first and second HCP ranged from
0.6 in Namibian-non-black and 1.4 in Namibian-black women to 3 in
Zambia and 5 in Nigeria.
3.6 | Woman-level correlates of the diagnostic
journey length
Women-level correlates of the diagnostic journey length were ana-
lyzed excluding screen-detected/CBE women. Minimally adjusted and
fully adjusted analyses yielded similar IRR estimates and hence only
findings from the latter are presented (Table 3). The length of the
diagnostic journey increased by 32% per every 10-year increase in
age at diagnosis (IRR: 1.32, 95% CI: 1.02-1.69). The diagnostic journey
was 12% longer (IRR: 1.12, 95% CI: 1.00-1.25) among women of low
relative to those of medium/high socioeconomic position (SEP) and
24% longer (1.24, 1.10-1.40) among those with primary/none relative
to those with higher education, both driven mainly by longer post-
contact intervals. The association with low education was particularly
marked in Namibian-black (1.47, 1.16-1.86) and Zambian (1.37,
1.00-1.87) women. Being unmarried was associated with a longer
diagnostic journey in Namibian-black and non-black women, but with
a shorter journey in Nigeria.
The length of the diagnostic journey decreased by about half
(0.56, 0.47-0.67) if a woman attributed her initial symptom(s) to can-
cer, reflecting both shorter pre- and post-contact intervals. Belief in
traditional medicine was associated with a longer (1.42, 1.11-1.81)
diagnostic journey in Nigeria, driven mainly by a longer post-contact
interval, but with a shorter (0.24, 0.06-0.91) journey in Namibian-non-
black women, reflecting both shorter pre- and post-contact intervals.
In Uganda, the only setting with a sizeable Muslim population, Muslim
women had a shorter diagnostic journey (0.76, 0.60-0.97), reflecting a
shorter post-contact interval. Being HIV-positive was associated with
a longer diagnostic journey in Zambia (1.77, 1.17-2.68; HIV preva-
lence: 15.1%), driven by longer pre- and post-contact intervals, but no
association was found for Namibian-black or Ugandan women, who
had similar HIV-prevalence (13.2% and 11.8%, respectively). Noticing
a breast lump as the first symptom was associated with a longer pre-
contact interval. Visiting first an informal HCP was associated with a
longer diagnostic journey, reflecting a longer post-contact interval.
The absolute difference (AD) in the median length of the diag-
nostic journey between women with low vs high education was
3.6 months, and between those who attributed their symptoms to
cancer vs those did not was 4.1 months, translating into AD in the
proportion diagnosed ≤3 months of 20% and 22%, respectively
(Figure 3). Hence, the AD in median lengths of the diagnostic jour-
ney between higher-educated women who attributed their symp-
toms to cancer and lower-educated women who did not was
7.2 months, corresponding to a 34% AD in the proportion diagnosed
≤3 months.
F IGURE 3 Percentage of ABC-DO
symptomatic women diagnosed within
3 months from the time of their symptom
recognition by: A, whether the woman
suspected first symptom might be
cancer; B, the woman's highest level of
formal education; and c, combined
education and suspicion of cancer, where
lower education is none/primary and
higher education is secondary or more
[Color figure can be viewed at
wileyonlinelibrary.com]
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4 | DISCUSSION
The diagnostic journey of ABC-DOwomen was much longer than reported
for white and black women in North America,11-28 stretching back to the
1940 to 1960s, but consistent with those reported for black women in
SSA29-38 (Supplemental Material). The post-contact interval accounted for
over 60% of the diagnostic journey in all settings except Nigeria, the sole
sites with regional rather than national catchment population, consistent
with considerable delays after a woman's first HCP contact and in line with
the high proportion of women reporting an inappropriate outcome of their
first HCP visit. The prolonged post-contact interval mainly reflected long
intervals between visits to a few HCP, rather than visits to multiple
HCPs. These findings highlight the importance of educating primary
and secondary health-care professionals about BC, and the need for
health-system implementation of clear referral pathways to fast-track
patients with suspicious breast abnormalities to specialized centers
for early diagnosis.
Identified woman-level correlates of prolonged time to diagnosis
were consistent with recent literature,6,39 with higher SEP being associ-
ated with shorter diagnostic journeys. Attributing the initial symptom(s)
to cancer was associated with shorter time to diagnosis independently
of educational level, indicating that improvement of a woman's BC
awareness should be a priority, particularly among socioeconomic dis-
advantaged populations. Contrary to studies in HICs,40,41 women
whose initial symptom was a lump experienced a longer pre-contact
interval. Being married was associated with shorter diagnostic journeys
in Namibia and Uganda. In contrast, being married and, consistent with
the low level of BC awareness, believing in traditional medicine were
associated with longer diagnostic journeys in Nigeria.9 Being HIV+ was
associated with a longer diagnostic journey in Zambia, but not in the
other two populations with high HIV-prevalence (Namibian-blacks and
Uganda), reflecting perhaps between-setting differences in health-care
access for HIV+ patients. Treatment and transport costs were the main
self-reported barriers to first visiting a HCP in Namibia and Uganda,
where women often had to travel long-distances to access health care.
ABC-DO is the largest study yet to quantify the length of the diag-
nostic journey, and its components, across a range of different SSA set-
tings, and the first to examine their relationship with stage at diagnosis.8
A major strength was the use of a specifically tailored m-health applica-
tion to collect time-annotated events through a woman's diagnostic jour-
ney and information on potential correlates of its length. Weaknesses
include the fact that participants were recruited in public tertiary referral
centers and thus might be unrepresentative as not all BC patients are
referred to these hospitals or can reach them (eg, lack of resources, early
death). Furthermore, the self-reported length of the diagnostic journey
might have been affected by between-woman variation in the ability to
recognize symptoms (eg, among women with a similar diagnosis journey
length mean tumor size was smaller among the more educated than
among less-educated women8) and across settings (eg, the percent of
cancers diagnosed at stages III/IV among women who reported a pre-
contact interval of ≤3 months ranged from 21% in Namibian-non-black
women to 54% in Nigerian and Namibian-black women). In particular,
the relatively short diagnostic journey in Nigeria seems at odds with the
very high percent of women diagnosed with advanced disease (76%),
suggesting later recognition (or admission) of symptoms, perhaps due to
poorer BC awareness, greater fear and stigma or faster tumor growth
associated with more aggressive tumor subtypes—the lack of immuno-
histochemistry testing in the Nigerian settings precluded examination of
this. Reassuringly, overall, the self-reported length of the diagnostic jour-
ney was associated with tumor stage at diagnosis.
In summary, the diagnostic journeys of women with symptoms
suspicious of BC, a disease that is a potentially curable if diagnosed
and treated early, are unacceptably long in SSA. Priority should be
given to promotion of BC awareness among both women and
front-line health-care workers and implementation of accelerated
mechanisms for referral of women with suspicious abnormalities to
specialized centers for early diagnosis and treatment.
ACKNOWLEDGMENTS
We would like to thank all ABC-DO participants for their time and all
ABC-DO study interviewers for their dedicated work. The ABC-DO
study was funded by Susan G Komen (IIR 13264158 to Valerie
McCormack and Isabel dos-Santos-Silva, GSP18IARC001 and
GSP19IARC001, and as part of “Implementing breast cancer care effi-
ciency in Zambia through specialized health provider training and m-
health evaluation of patient outcomes” for the Zambian site to
Groesbeck Parham) and by the International Agency for Research on
Cancer. Moses Galukande is a THRiVE-2 fellow (supported by DELTA
African initiative DEL-15-011). Leeya Pinder is supported by the Uni-
versity of Washington T32 Fellowship (5T32CA009515-34).
CONFLICT OF INTEREST
All authors declared no potential conflicts of interest. Where authors
are identified as personnel of the International Agency for Research
on Cancer/World Health Organization, the authors alone are respon-
sible for the views expressed in this article and they do not necessarily
represent the decisions, policy or views of the International Agency
for Research on Cancer/World Health Organization.
ETHICS STATEMENT
The study was approved by all local and institutional ethics committees.7
Participants provided written informed consent or, if illiterate, a fingerprint.
DATA AVAILABILITY STATEMENT
Collaborations with ABC-DO at IARC are welcome. Please email
mccormackv@iarc.fr
ORCID
Milena Foerster https://orcid.org/0000-0003-3912-1718
Valerie McCormack https://orcid.org/0000-0001-7397-3442
REFERENCES
1. Edge SBBD, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC
Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
2. dos-Santos-Silva I, De Stavola BL, Junior NLR, et al. Ethnoracial and
social trends in breast cancer staging at diagnosis in Brazil, 2001–14:
a case only analysis. Lancet Glob Health. 2019;7(6):e784-e797.
350 FOERSTER ET AL.
3. Jedy-Agba E, McCormack V, Adebamowo C, Dos-Santos-Silva I. Stage
at diagnosis of breast cancer in sub-Saharan Africa: a systematic
review and meta-analysis. Lancet Glob Health. 2016;4(12):e923-e935.
4. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ.
Influence of delay on survival in patients with breast cancer: a sys-
tematic review. Lancet. 1999;353(9159):1119-1126.
5. Anderson BO, Cazap E, El Saghir NS, et al. Optimisation of breast can-
cer management in low-resource and middle-resource countries:
executive summary of the Breast Health Global Initiative consensus,
2010. Lancet Oncol. 2011;12(4):387-398.
6. Espina C, McKenzie F, Dos-Santos-Silva I. Delayed presentation and
diagnosis of breast cancer in African women: a systematic review.
Ann Epidemiol. 2017;27(10):659-671.e7.
7. McKenzie F, Zietsman A, Galukande M, et al. African Breast Cancer—
Disparities in Outcomes (ABC-DO): protocol of a multicountry mobile
health prospective study of breast cancer survival in sub-Saharan
Africa. BMJ Open. 2016;6(8):e011390.
8. McKenzie F, Zietsman A, Galukande M, et al. Drivers of advanced
stage at breast cancer diagnosis in the multicountry African breast
cancer - disparities in outcomes (ABC-DO) study. Int J Cancer. 2018;
142(8):1568-1579.
9. McKenzie F, Zietsman A, Galukande M, et al. Breast cancer awareness
in the sub-Saharan African ABC-DO cohort: African Breast Cancer—
Disparities in Outcomes study. Cancer Causes Control. 2018;29(8):
721-730.
10. European Network of Cancer Registries. Recommendations for Cod-
ing Incidence Date; 1997. Retrieved from http://www.encr.eu/
images/docs/recommendations/incideng.pdf
11. Potts WJ. Results of delay in treatment of breast cancer. Ann Surg.
1928;88(5):842-844.
12. Higginson J. Patient delay with reference to stage of cancer. Cancer.
1962;15:50-56.
13. Wilkinson GS, Edgerton F, Wallace HJ Jr, Reese P, Patterson J,
Priore R. Delay, stage of disease and survival from breast cancer.
J Chronic Dis. 1979;32(5):365-373.
14. Elwood JM, Moorehead WP. Delay in diagnosis and long-term sur-
vival in breast cancer. Br Med J. 1980;280(6227):1291-1294.
15. Dennis CR, Gardner B, Lim B. Analysis of survival and recurrence
vs. patient and doctor delay in treatment of breast cancer. Cancer.
1975;35(3):714-720.
16. Buttlar CA, Templeton AC. The size of breast masses at presentation.
The impact of prior medical training. Cancer. 1983;51(9):1750-1753.
17. Feldman JG, Saunders M, Carter AC, Gardner B. The effects of
patient delay and symptoms other than a lump on survival in breast
cancer. Cancer. 1983;51(7):1226-1229.
18. Huguley CM Jr, Brown RL, Greenberg RS, Clark WS. Breast self-
examination and survival from breast cancer. Cancer. 1988;62(7):
1389-1396.
19. Vernon SW, Tilley BC, Neale AV, Steinfeldt L. Ethnicity, survival, and
delay in seeking treatment for symptoms of breast cancer. Cancer.
1985;55(7):1563-1571.
20. Freeman HP, Wasfie TJ. Cancer of the breast in poor black women.
Cancer. 1989;63(12):2562-2569.
21. Coates RJ, Bransfield DD, Wesley M, et al. Differences between black
and white women with breast cancer in time from symptom recogni-
tion to medical consultation. J Natl Cancer Inst. 1992;84(12):938-950.
22. Hunter CP, Redmond CK, Chen VW, et al. Breast cancer: factors
associated with stage at diagnosis in black and white women. J Natl
Cancer Inst. 1993;85(14):1129-1137.
23. Caplan LS, Helzlsouer KJ, Shapiro S, Freedman LS, Coates RJ,
Edwards BK. System delay in breast cancer in whites and blacks.
Am J Epidemiol. 1995;142(8):804-812.
24. Rayson D, Chiasson D, Dewar R. Elapsed time from breast cancer
detection to first adjuvant therapy in a Canadian province,
1999-2000. CMAJ. 2004;170(6):957-961.
25. Gorin SS, Heck JE, Cheng B, Smith SJ. Delays in breast cancer diagno-
sis and treatment by racial/ethnic group. Arch Intern Med. 2006;166
(20):2244-2252.
26. Partridge AH, Hughes ME, Ottesen RA, et al. The effect of age on
delay in diagnosis and stage of breast cancer. Oncologist. 2012;17(6):
775-782.
27. Gregorio DI, Cummings KM, Michalek A. Delay, stage of disease, and
survival among White and Black women with breast cancer.
Am J Public Health. 1983;73(5):590-593.
28. Robbins GF, Bross I. The significance of delay in relation to prognosis
of patients with primary operable breast cancer. Cancer. 1957;10(2):
338-344.
29. Ly M, Diop S, Sacko M, Baby M, Diop CT, Diallo DA. Breast cancer:
factors influencing the therapeutic itinerary of patients in a medical
oncology unit in Bamako (Mali). Bull Cancer. 2002;89(3):323-326.
30. Clegg-Lamptey J, Dakubo J, Attobra YN. Why do breast cancer
patients report late or abscond during treatment in Ghana? A pilot
study. Ghana Med J. 2009;43(3):127-131.
31. Ezeome ER. Delays in presentation and treatment of breast cancer in
Enugu, Nigeria. Niger J Clin Pract. 2010;13(3):311-316.
32. Ibrahim NA, Oludara MA. Socio-demographic factors and reasons
associated with delay in breast cancer presentation: a study in Nige-
rian women. Breast. 2012;21(3):416-418.
33. Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW.
Cancer care challenges in developing countries. Cancer. 2012;118
(14):3627-3635.
34. Toure M, Nguessan E, Bambara AT, Kouassi YK, Dia JM,
Adoubi I. Factors linked to late diagnosis in breast cancer in sub-Saharan
Africa: case of Cote d'Ivoire. Gynecol Obstet Fertil. 2013;41(12):696-700.
35. Marcus TS, Lunda S, Fernandez L. Delayed breast cancer presenta-
tion: hospital data should inform proactive primary care. Afr J Prim
Health Care Fam Plan. 2013;5:503.
36. Pace LE, Mpunga T, Hategekimana V, et al. Delays in breast cancer
presentation and diagnosis at two rural cancer referral centers in
Rwanda. Oncologist. 2015;20(7):780-788.
37. Brinton L, Figueroa J, Adjei E, et al. Factors contributing to delays in
diagnosis of breast cancers in Ghana, West Africa. Breast Cancer Res
Treat. 2017;162(1):105-114.
38. Joffe M, Ayeni O, Norris SA, et al. Barriers to early presentation of
breast cancer among women in Soweto, South Africa. PLoS One.
2018;13(2):e0192071.
39. Unger-Saldana K, Infante-Castaneda C. Delay of medical care for
symptomatic breast cancer: a literature review. Salud Publica Mex.
2009;51(Suppl 2):s270-s285.
40. Burgess CC, Ramirez AJ, Richards MA, Love SB. Who and what influ-
ences delayed presentation in breast cancer? Br J Cancer. 1998;77(8):
1343-1348.
41. Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P,
Richards MA. Factors predicting delayed presentation of symptomatic
breast cancer: a systematic review. Lancet. 1999;353(9159):1127-1131.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Foerster M, McKenzie F, Zietsman A,
et al. Dissecting the journey to breast cancer diagnosis in sub-
Saharan Africa: Findings from the multicountry ABC-DO
cohort study. Int. J. Cancer. 2021;148:340–351. https://doi.
org/10.1002/ijc.33209
FOERSTER ET AL. 351
